TopicalDosed ingredientTherapeutic flag
Capsaicin
CAS 404-86-4
Capsaicin (CAS 404-86-4) is a Phase 4 pharmaceutical compound with 11 bioactivity targets and 1,576 adverse event associations.
SOURCE
NLM DailyMed
Label records
1
SOURCE
EMBL-EBI ChEMBL
Bioactivity
21
SOURCE
DrugCentral
Adverse signals
1,576
SOURCE
IUPHAR/BPS
PubMed IDs
5
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Primary Name
Capsaicin
CAS Number
404-86-4
UNII
S07O44R1ZM
InChIKey
YKPUWZUDDOIDPM-SOFGYWHQSA-N
ChEMBL ID
CHEMBL294199
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
dosed ingredientnatural producttherapeutic flagtopical
SOURCE
EMBL-EBI ChEMBL
B25820EEF0F0
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL294199 | Small molecule
SOURCE
NLM DailyMed
1 label row
Drug Label Active Ingredients
Active ingredient and active moiety rows from source drug product labels.
| Product | Ingredient | Active Moiety | Effective |
|---|---|---|---|
| New Terocin | CAPSAICIN S07O44R1ZM |
CAPSAICIN | 20260505 |
SOURCE
EMBL-EBI ChEMBL
21 bioactivity rows
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | AC50 | 28074.608571428573 nM | 70 | - |
| - | Potency | 28551.073214285716 nM | 44 | - |
| - | IC50 | 35772.610512820516 nM | 38 | - |
| - | EC50 | 2027.7712352941176 nM | 32 | - |
| - | Ki | 5961.714285714285 nM | 14 | - |
| - | MIC | 50 ug.mL-1 | 5 | - |
| - | MIC | 63000 nM | 1 | - |
| Transient receptor potential cation channel subfamily V member 1 Ion channel |
Ki | 8.22 | - | Homo sapiens |
| Prostaglandin G/H synthase 1 Enzyme |
IC50 | 5.42 | - | Homo sapiens |
| Cytochrome P450 1A2 Enzyme |
IC50 | 5.523 | - | Homo sapiens |
| Arachidonate 5-lipoxygenase Enzyme |
IC50 | 4.25 | - | Homo sapiens |
| Potassium voltage-gated channel subfamily A member 1 Ion channel |
IC50 | 4.54 | - | Homo sapiens |
| Tyrosine--tRNA ligase, cytoplasmic Enzyme |
Ki | 4.38 | - | Homo sapiens |
| Transient receptor potential cation channel subfamily V member 1 Ion channel |
Ki | 5.77 | - | Rattus norvegicus |
| Lysine-specific histone demethylase 1A Enzyme |
IC50 | 6.22 | - | Homo sapiens |
| NADH-ubiquinone oxidoreductase chain 1 Unclassified |
IC50 | 4.28 | - | Bos taurus |
| Transient receptor potential cation channel subfamily M member 8 Ion channel |
IC50 | 4.55 | - | Mus musculus |
| Transient receptor potential cation channel subfamily V member 1 Ion channel |
EC50 | 8 | - | Mus musculus |
| Potassium voltage-gated channel subfamily A member 7 Ion channel |
IC50 | 4.6 | - | Mus musculus |
| Potassium voltage-gated channel subfamily A member 1 Ion channel |
IC50 | 4.5 | - | Mus musculus |
| Potassium voltage-gated channel subfamily A member 2 Ion channel |
Kd | 4.4 | - | Rattus norvegicus |
SOURCE
DrugCentral
66 associations
Adverse Event Associations
DrugCentral / FAERS disproportionality signal rows matched to this compound.
| Reaction PT | Drug AE | LLR | MedDRA |
|---|---|---|---|
| Application site pain | 125 | 519.009 | 10003051 |
| Application site erythema | 70 | 241.763 | 10003041 |
| Body tinea | 49 | 211.458 | 10005913 |
| Infection susceptibility increased | 49 | 175.09 | 10021866 |
| Application site burn | 36 | 165.324 | 10065059 |
| Inhibitory drug interaction | 47 | 162.369 | 10068071 |
| Glucose tolerance impaired | 49 | 136.204 | 10018429 |
| Application site vesicles | 32 | 125.057 | 10048941 |
| Impaired quality of life | 53 | 117.218 | 10076936 |
| Poor quality sleep | 59 | 115.446 | 10062519 |
| Bone density decreased | 49 | 109.633 | 10049470 |
| Purpura | 51 | 105.976 | 10037549 |
| Impaired work ability | 51 | 100.062 | 10052302 |
| Hyperlipidaemia | 53 | 90.606 | 10062060 |
| Oral herpes | 52 | 87.312 | 10067152 |
| Occupational exposure to product | 24 | 76.278 | 10073311 |
| Burns second degree | 23 | 72.357 | 10006802 |
| Skin disorder | 50 | 69.885 | 10040831 |
| Cataract | 61 | 60.511 | 10007739 |
| Burning sensation | 55 | 58.03 | 10006784 |
| Application site hyperaesthesia | 6 | 49.021 | 10050100 |
| Urticaria thermal | 11 | 48.572 | 10061399 |
| Herpes zoster | 64 | 48.041 | 10019974 |
| Cellulitis | 65 | 44.539 | 10007882 |
| Insomnia | 106 | 42.756 | 10022437 |
| Application site swelling | 11 | 39.281 | 10053424 |
| Application site necrosis | 6 | 38.616 | 10003048 |
| Administration site erythema | 10 | 36.409 | 10074796 |
| Burns first degree | 6 | 35.955 | 10006797 |
| Weight increased | 107 | 34.08 | 10047899 |
| Nail bed tenderness | 8 | 32.926 | 10049268 |
| Immune thrombocytopenia | 23 | 31.987 | 10083842 |
| Contusion | 68 | 31.186 | 10050584 |
| Hypertension | 111 | 29.395 | 10020772 |
| Therapy non-responder | 50 | 28.55 | 10051082 |
| Application site warmth | 6 | 26.48 | 10003060 |
| Pigmentation disorder | 14 | 25.752 | 10062080 |
| Blood pressure systolic increased | 41 | 25.662 | 10005760 |
| Application site oedema | 5 | 25.316 | 10003050 |
| Throat irritation | 30 | 24.275 | 10043521 |
| Osteoarthritis | 46 | 23.817 | 10031161 |
| Hypercholesterolaemia | 23 | 23.5 | 10020603 |
| Complement factor C4 decreased | 6 | 23.433 | 10050983 |
| Allodynia | 8 | 21.72 | 10053552 |
| Vulvovaginal swelling | 6 | 21.257 | 10071211 |
| Blood viscosity abnormal | 5 | 21.159 | 10074728 |
| Illness | 31 | 21.145 | 10080284 |
| Application site discolouration | 7 | 20.518 | 10059005 |
| Autonomic neuropathy | 8 | 19.481 | 10061666 |
| Erythema | 70 | 19.167 | 10015150 |
Association rows are source-linked signal records, not incidence rates or clinical causality claims.
SOURCE
IUPHAR/BPS
8 interactions
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| TRPV1 TRPV1 |
Agonist | 7.5 pEC50 | 15306801 |
| CFTR CFTR |
Potentiation | - | - |
| K v 1.1 Kcna1 |
Channel blocker | 4.5 pIC50 | 7517498 |
| K v 1.2 Kcna2 |
Pore blocker | 4.400000095367432 pKd | 7517498 |
| K v 1.7 Kcna7 |
Channel blocker | 4.6 pIC50 | 9488722 |
| K v 3.1 Kcnc1 |
Channel blocker | 3.8 pIC50 | 7517498 |
| TRPV1 Trpv1 |
Agonist | 8.0 pEC50 | 15489017 |
| TRPV1 Trpv1 |
Agonist | 6.1 pEC50 | 9349813 |
SOURCE
NLM RxNorm
4 name rows
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| CAPSAICIN | 1992 | SU | MTHSPL |
| capsaicin | 1992 | SU | MTHSPL |
| Capsaicin | 1992 | SU | MTHSPL |
| capsaicin | 1992 | IN | RXNORM |
SOURCE
SIDER
80 side-effect rows
Side Effects
SIDER side-effect terms mapped to the drug or same-CAS compound identity.
| Side Effect | Drug Name | MedDRA Type | Concept ID |
|---|---|---|---|
| Angiopathy | capsaicin | LLT | C0042373 |
| Angiopathy | capsaicin | PT | C0042373 |
| Application site anaesthesia | capsaicin | LLT | C0234943 |
| Application site anaesthesia | capsaicin | PT | C0234943 |
| Application site burn | capsaicin | LLT | C0877661 |
| Application site burn | capsaicin | PT | C0877661 |
| Application site dryness | capsaicin | LLT | C0877098 |
| Application site dryness | capsaicin | PT | C0877098 |
| Application site erosion | capsaicin | PT | C1696574 |
| Application site erythema | capsaicin | LLT | C0853700 |
| Application site erythema | capsaicin | PT | C0853700 |
| Application site excoriation | capsaicin | LLT | C1142498 |
| Application site exfoliation | capsaicin | LLT | C1610049 |
| Application site exfoliation | capsaicin | PT | C1610049 |
| Application site haematoma | capsaicin | LLT | C0877095 |
| Application site haematoma | capsaicin | PT | C0877095 |
| Application site hyperaesthesia | capsaicin | LLT | C0919600 |
| Application site hyperaesthesia | capsaicin | PT | C0919600 |
| Application site inflammation | capsaicin | LLT | C0877126 |
| Application site inflammation | capsaicin | PT | C0877126 |
| Application site irritation | capsaicin | LLT | C0521490 |
| Application site irritation | capsaicin | PT | C0521490 |
| Application site oedema | capsaicin | LLT | C0234936 |
| Application site oedema | capsaicin | PT | C0234936 |
| Application site pain | capsaicin | LLT | C0521491 |
| Application site pain | capsaicin | PT | C0521491 |
| Application site pain | capsaicin | PT | C0521491 |
| Application site papules | capsaicin | LLT | C0877127 |
| Application site papules | capsaicin | PT | C0877127 |
| Application site paraesthesia | capsaicin | LLT | C0877096 |
| Application site paraesthesia | capsaicin | PT | C0877096 |
| Application site pruritus | capsaicin | LLT | C0853714 |
| Application site pruritus | capsaicin | PT | C0853714 |
| Application site rash | capsaicin | LLT | C0521495 |
| Application site rash | capsaicin | PT | C0521495 |
| Application site reaction | capsaicin | LLT | C0151505 |
| Application site reaction | capsaicin | PT | C0151505 |
| Application site swelling | capsaicin | LLT | C1096001 |
| Application site swelling | capsaicin | PT | C1096001 |
| Application site urticaria | capsaicin | LLT | C0919603 |
| Application site urticaria | capsaicin | PT | C0919603 |
| Application site vesicles | capsaicin | LLT | C0877097 |
| Application site vesicles | capsaicin | PT | C0877097 |
| Application site warmth | capsaicin | LLT | C0858794 |
| Application site warmth | capsaicin | PT | C0858794 |
| Blood pressure increased | capsaicin | LLT | C0497247 |
| Blood pressure increased | capsaicin | PT | C0497247 |
| Bronchitis | capsaicin | LLT | C0006277 |
| Bronchitis | capsaicin | PT | C0006277 |
| Burning sensation | capsaicin | LLT | C0085624 |
| Burning sensation | capsaicin | PT | C0085624 |
| Burns second degree | capsaicin | LLT | C0332687 |
| Burns second degree | capsaicin | PT | C0332687 |
| Cardiac disorder | capsaicin | LLT | C0018799 |
| Cardiac disorder | capsaicin | PT | C0018799 |
| Connective tissue disorder | capsaicin | LLT | C0009782 |
| Connective tissue disorder | capsaicin | PT | C0009782 |
| Cough | capsaicin | LLT | C0010200 |
| Cough | capsaicin | PT | C0010200 |
| Dizziness | capsaicin | LLT | C0012833 |
| Dizziness | capsaicin | PT | C0012833 |
| Dysgeusia | capsaicin | LLT | C0013378 |
| Dysgeusia | capsaicin | PT | C0013378 |
| Erythema | capsaicin | LLT | C0041834 |
| Erythema | capsaicin | PT | C0041834 |
| Eye disorder | capsaicin | LLT | C0015397 |
| Eye disorder | capsaicin | PT | C0015397 |
| Eye irritation | capsaicin | LLT | C0235266 |
| Eye irritation | capsaicin | PT | C0235266 |
| Eye pain | capsaicin | LLT | C0151827 |
| Eye pain | capsaicin | PT | C0151827 |
| Gastrointestinal disorder | capsaicin | LLT | C0017178 |
| Gastrointestinal disorder | capsaicin | PT | C0017178 |
| HIV associated nephropathy | capsaicin | LLT | C0078911 |
| HIV associated nephropathy | capsaicin | PT | C0078911 |
| Headache | capsaicin | LLT | C0018681 |
| Headache | capsaicin | PT | C0018681 |
| Herpes zoster | capsaicin | LLT | C0019360 |
| Herpes zoster | capsaicin | PT | C0019360 |
| Hyperaesthesia | capsaicin | LLT | C0020453 |
SOURCE
Rendered pharma page rows
FAQPage JSON-LD
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Capsaicin used for in pharmaceutical contexts?
Capsaicin (CAS 404-86-4) appears in DailyMed active-ingredient label rows, including New Terocin.
What are the known adverse events for Capsaicin?
Capsaicin has 1,576 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Application site pain, Application site erythema, Body tinea, Infection susceptibility increased, Application site burn. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Capsaicin also used in cosmetics?
No same-CAS cosmetics profile is rendered from the ingredients-table cross-reference for Capsaicin.
What clinical phase is Capsaicin in?
Capsaicin is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Capsaicin?
Capsaicin has 21 bioactivity rows in this page query. Rendered target entries include Transient receptor potential cation channel subfamily V member 1, Prostaglandin G/H synthase 1, Cytochrome P450 1A2, Arachidonate 5-lipoxygenase, Potassium voltage-gated channel subfamily A member 1.